title: Serum Abeta levels as predictors of conversion to mild cognitive impairment/Alzheimer disease in an ADAPT subcohort.
abstract: Recent evidence suggests an association of beta-amyloid (Abeta) with vascular risk factors and the medications to treat them, which could potentially obfuscate the usefulness of Abeta for prediction of mild cognitive impairment (MCI) or Alzheimer disease (AD). In a subcohort from the Alzheimer's Disease Anti-inflammatory Prevention Trial (enriched for family history of AD), we investigated whether systolic blood pressure, total cholesterol, triglycerides, serum creatinine, apolipoprotein E, and use of statins and antihypertensives influenced the predictive value of serum Abeta for MCI/AD during a 2-year period. We collected blood samples to quantify serum Abeta from cognitively normal participants (n = 203) at baseline and ascertained the outcome of MCI/AD (n = 24) for a period of approximately 2 years. In an unadjusted model, the lowest quartile of Abeta(1-42) (hazard ratio [HR] = 2.93, 95% CI [1.02-8.32], P = 0.04) and of the Abeta(1-42)/Abeta(1-40) ratio (HR = 3.53, 95% CI [1.24-10.07], P = 0.02), compared with the highest quartile, predicted conversion to MCI/AD, but no impact of Abeta(1-40) was observed. No relationship between nonsteroidal antiinflammatory drug interventions and Abeta on MCI/AD risk was evident. Once data were adjusted for potential confounders (age, sex, and education), vascular risk factors, and the medications listed above, the lowest quartiles of Abeta(1-42) (HR = 4.47, 95% CI [1.39-14.39], P = 0.01), and of the Abeta(1-42/)Abeta(1-40) ratio (HR 4.87, 95% CI [1.50-15.87], P = 0.01) became strong predictors of conversion to MCI/AD. In this subcohort of individuals at risk for AD, the association of Abeta with vascular risk factors and medications to treat these conditions did not interfere with Abeta's predictive value for MCI/AD.
authors.affiliation: Roskamp Institute, Sarasota, Florida 34243, USA. labdullah@rfdn.org
authors.forename: Laila
authors.initials: L
authors.lastname: Abdullah
authors.forename: Cheryl
authors.initials: C
authors.lastname: Luis
authors.forename: Daniel
authors.initials: D
authors.lastname: Paris
authors.forename: Benoit
authors.initials: B
authors.lastname: Mouzon
authors.forename: Ghania
authors.initials: G
authors.lastname: Ait-Ghezala
authors.forename: Andrew P
authors.initials: AP
authors.lastname: Keegan
authors.forename: Duolao
authors.initials: D
authors.lastname: Wang
authors.forename: Fiona
authors.initials: F
authors.lastname: Crawford
authors.forename: Michael
authors.initials: M
authors.lastname: Mullan
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000097:blood* / Q000175:diagnosis / Q000453:epidemiology; D016229:Amyloid beta-Peptides / Q000097:blood*; D015331:Cohort Studies; D003704:Dementia / Q000097:blood / Q000175:diagnosis; D005260:Female; D006801:Humans; D008297:Male; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D012307:Risk Factors
chemical_list: D016229:Amyloid beta-Peptides
references.citation: Neurology. 1989 Sep;39(9):1159-65
references.pmid: 2771064
references.citation: Arch Neurol. 2007 Aug;64(8):1130-8
references.pmid: 17698703
references.citation: Neurology. 2009 Jun 2;72(22):1899-905
references.pmid: 19386997
references.citation: Gerontology. 2003 Nov-Dec;49(6):374-9
references.pmid: 14624066
references.citation: Ann Neurol. 2009 Apr;65(4):403-13
references.pmid: 19296504
references.citation: Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S7-S14
references.pmid: 18632005
references.citation: Mol Med. 2000 May;6(5):430-9
references.pmid: 10952022
references.citation: Arch Intern Med. 2002 Oct 14;162(18):2046-52
references.pmid: 12374512
references.citation: Neurology. 2008 May 6;70(19):1664-71
references.pmid: 18401021
references.citation: World J Biol Psychiatry. 2005;6(2):85-97
references.pmid: 16156481
references.citation: J Psychiatr Res. 2008 Sep;42(11):946-55
references.pmid: 18155247
references.citation: Neurology. 1984 Jul;34(7):939-44
references.pmid: 6610841
references.citation: Arch Neurol. 2001 Dec;58(12):1985-92
references.pmid: 11735772
references.citation: CNS Spectr. 2008 Jan;13(1):45-53
references.pmid: 18204414
references.citation: Arch Neurol. 2008 Jul;65(7):896-905
references.pmid: 18474729
references.citation: Neurology. 2009 May 19;72(20):1727-34
references.pmid: 19228584
references.citation: Neurology. 2008 Jun 10;70(24):2291-8
references.pmid: 18509093
references.citation: Drug Discov Today. 2009 Mar;14(5-6):241-51
references.pmid: 19135168
references.citation: Arch Neurol. 2007 Mar;64(3):354-62
references.pmid: 17353377
references.citation: Neuroimage. 2009 Apr 15;45(3):645-55
references.pmid: 19280686
references.citation: Arch Clin Neuropsychol. 2006 Feb;21(2):151-60
references.pmid: 16202560
references.citation: Am J Geriatr Psychiatry. 2008 Nov;16(11):883-92
references.pmid: 18978249
references.citation: J Alzheimers Dis. 2004 Dec;6(6):585-9; discussion 673-81
references.pmid: 15665398
references.citation: Arch Neurol. 1999 Mar;56(3):303-8
references.pmid: 10190820
references.citation: Lancet Neurol. 2006 Aug;5(8):655-60
references.pmid: 16857570
references.citation: Neurology. 2008 Jan 1;70(1):17-24
references.pmid: 18003940
references.citation: J Neurol Neurosurg Psychiatry. 2009 Jan;80(1):13-7
references.pmid: 18931004
references.citation: Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14052-7
references.pmid: 18779561
references.citation: Br J Clin Pharmacol. 2009 Jan;67(1):99-109
references.pmid: 19006546
references.citation: Mol Med. 2009 Mar-Apr;15(3-4):95-100
references.pmid: 19081767
references.citation: Neurology. 2007 May 22;68(21):1800-8
references.pmid: 17460158
references.citation: Ann Intern Med. 2002 Aug 6;137(3):149-55
references.pmid: 12160362